Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.22%0700.HK-6.09%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.04%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.27%0857.HK-1.46%UNH-10.21%1288.HK-1.27%PM-0.85%0005.HK-1.87%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.66%AUDUSD-1.51%EURAUD+1.03%AUDCHF-1.00%AUDNZD-0.98%AUDCAD-0.97%GBPAUD+0.96%GBPJPY-0.71%NZDJPY-0.71%CADJPY-0.70%EURJPY-0.67%CHFJPY-0.66%AUDSGD-0.63%AUDDKK-0.58%USDCAD+0.55%USDCHF+0.53%GBPUSD-0.53%NZDUSD-0.53%EURUSD-0.50%AUDNOK-0.47%GBPTRY+0.41%NZDMXN+0.39%USDMXN+0.32%GBPHKD+0.32%USDZAR+0.30%GBPMXN-0.28%USDTHB+0.25%EURZAR+0.24%GBPZAR+0.22%USDTRY+0.21%USDJPY-0.18%CHFNOK+0.17%USDILS+0.16%USDNOK+0.15%USDCNH-0.13%NOKJPY-0.11%CHFSEK+0.10%EURNOK+0.10%EURCNH-0.10%USDPLN+0.09%USDSEK+0.09%NZDSGD+0.09%GBPSGD-0.07%EURHKD-0.06%USDDKK+0.05%EURGBP+0.05%EURCAD+0.05%EURSGD-0.05%PLNJPY-0.05%SGDJPY+0.05%EURSEK+0.04%EURCZK+0.04%USDCOP-0.04%EURCHF+0.04%EURPLN+0.04%EURNZD+0.03%NZDCHF-0.03%CADCHF-0.02%CHFSGD+0.02%USDHKD-0.01%GBPCHF-0.01%USDSGD+0.01%GBPCAD-0.01%NZDCAD0.00%GBPNZD0.00%EURDKK0.00%W1-0.76%XNGUSD-0.61%C1-0.55%UKOIL+0.52%S1-0.39%USOIL+0.32%XAUUSD+0.24%GAUUSD+0.24%XPTUSD-0.22%XAGUSD+0.20%GAGUSD+0.20%COTTON+0.15%BTCUSD-3.51%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-1.71%DOGEUSD+55.95%LINKUSD-3.40%XLMUSD-3.79%BCHUSDT-3.59%LTCUSD+47.50%UNIUSD-3.05%SUIUSD-3.20%TONUSD+59.18%HBARUSDT-5.05%TAOUSDT-3.41%AAVEUSD-3.74%ONDOUSDT-5.51%ICPUSDT-2.22%DOTUSDT-3.90%WLDUSDT-3.57%ARBUSDT-5.68%ATOMUSDT-2.50%INJUSDT-7.97%STXUSDT-3.10%PYTHUSDT-0.76%TIAUSDT-3.37%FETUSDT-4.46%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.56%OPUSDT-3.90%IOTAUSDT-2.66%POLUSDT-2.10%WIFUSDT-2.98%AXSUSDT-2.91%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.54%GALAUSDT-2.38%DYDXUSDT-2.63%ORDIUSDT-2.62%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.22%0700.HK-6.09%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.04%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.27%0857.HK-1.46%UNH-10.21%1288.HK-1.27%PM-0.85%0005.HK-1.87%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.66%AUDUSD-1.51%EURAUD+1.03%AUDCHF-1.00%AUDNZD-0.98%AUDCAD-0.97%GBPAUD+0.96%GBPJPY-0.71%NZDJPY-0.71%CADJPY-0.70%EURJPY-0.67%CHFJPY-0.66%AUDSGD-0.63%AUDDKK-0.58%USDCAD+0.55%USDCHF+0.53%GBPUSD-0.53%NZDUSD-0.53%EURUSD-0.50%AUDNOK-0.47%GBPTRY+0.41%NZDMXN+0.39%USDMXN+0.32%GBPHKD+0.32%USDZAR+0.30%GBPMXN-0.28%USDTHB+0.25%EURZAR+0.24%GBPZAR+0.22%USDTRY+0.21%USDJPY-0.18%CHFNOK+0.17%USDILS+0.16%USDNOK+0.15%USDCNH-0.13%NOKJPY-0.11%CHFSEK+0.10%EURNOK+0.10%EURCNH-0.10%USDPLN+0.09%USDSEK+0.09%NZDSGD+0.09%GBPSGD-0.07%EURHKD-0.06%USDDKK+0.05%EURGBP+0.05%EURCAD+0.05%EURSGD-0.05%PLNJPY-0.05%SGDJPY+0.05%EURSEK+0.04%EURCZK+0.04%USDCOP-0.04%EURCHF+0.04%EURPLN+0.04%EURNZD+0.03%NZDCHF-0.03%CADCHF-0.02%CHFSGD+0.02%USDHKD-0.01%GBPCHF-0.01%USDSGD+0.01%GBPCAD-0.01%NZDCAD0.00%GBPNZD0.00%EURDKK0.00%W1-0.76%XNGUSD-0.61%C1-0.55%UKOIL+0.52%S1-0.39%USOIL+0.32%XAUUSD+0.24%GAUUSD+0.24%XPTUSD-0.22%XAGUSD+0.20%GAGUSD+0.20%COTTON+0.15%BTCUSD-3.51%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-1.71%DOGEUSD+55.95%LINKUSD-3.40%XLMUSD-3.79%BCHUSDT-3.59%LTCUSD+47.50%UNIUSD-3.05%SUIUSD-3.20%TONUSD+59.18%HBARUSDT-5.05%TAOUSDT-3.41%AAVEUSD-3.74%ONDOUSDT-5.51%ICPUSDT-2.22%DOTUSDT-3.90%WLDUSDT-3.57%ARBUSDT-5.68%ATOMUSDT-2.50%INJUSDT-7.97%STXUSDT-3.10%PYTHUSDT-0.76%TIAUSDT-3.37%FETUSDT-4.46%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.56%OPUSDT-3.90%IOTAUSDT-2.66%POLUSDT-2.10%WIFUSDT-2.98%AXSUSDT-2.91%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.54%GALAUSDT-2.38%DYDXUSDT-2.63%ORDIUSDT-2.62%NOTUSDT+0.86%RONINUSDT-2.92%
MT

Mineralys Therapeutics, Inc. (MLYS)

NASDAQ • Healthcare

$13.78
-$0.7 (-4.8%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$14.4
Day Range$13.75 - $14.47
Avg. Volume (3M)1.9M
Market Cap$1.2B
52 Week Range
$13.75$45

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$369.9M
EPS (TTM)
-$4.36
ROA (TTM)
-58.71%
Current Ratio
11.83

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+7.8%Q2 2026-$0.47
-419.5%Q3 2026-$2.85
-15.4%Q4 2026-$0.64

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -15.4%

Mineralys Therapeutics’ earnings missed expectations as its third fiscal quarter of 2026 results, reported November 4, 2026, showed EPS of -$0.64 trailing the -$0.55 estimate by -$0.09, based on preliminary results. The quarter’s net loss widened, with net income down 55.2% year over year to roughly -$57.3 million versus -$36.9 million a year ago, and operating income coming in around -$60.1 million. EPS was down 23.1% from -$0.52 a year ago, consistent with the larger net loss for this clinical-stage biotechnology business focused on its lorundrostat program. Cash usage also remained significant, with negative operating cash flow of about -$43.1 million. For the next period, consensus calls for EPS of -$0.65 on revenue of $1.5 million.

View full earnings history

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops medicines for diseases driven by abnormally elevated aldosterone. In qualitative terms, it is a clinical-stage drug developer rather than a commercial biopharma business, with its work centered on cardiorenal disorders tied to excess aldosterone.

Name
Mineralys Therapeutics, Inc.
CEO
Jon Congleton
Industry
Healthcare
Year Founded
2019
Employees
76

Today's Snapshot

AI-generated

MLYS closed 4.8% below yesterday's close, in line with a weaker sector. The day ended with MLYS within 0.2% of its 52-week low of 13.75. Mineralys reported its blood-pressure drug sustained reductions ahead of an FDA decision.

Trading Volume

Below 10d avg (1.8M)

1.3M

vs S&P 500 Today

Strong Underperformance

-4.57%

Updated: November 18, 2026 at 21:10 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
MLYS shows a pronounced bearish alignment as the stock sits beneath virtually all moving averages, including the long-term averages, while ADX signals a developing downtrend. Momentum and MACD are negative, even though some short-term oscillators are oversold, which points to continued distribution rather than reversal. Volatility is elevated for the share price and OBV reflects persistent outflows, while the pivot lies above the current price and reinforces resistance. Technical takeaway: Strong Sell — downward trend with negative momentum and selling volume outweighing short-term oversold readings.
All signals
  • EMA (5 indicators)$15.38 - $26.30
    Sell
  • RSI (14)27.40
    Buy
  • Stochastic %K (14, 3, 3)1.20
    Buy
  • MACD Level (12, 26)-2.11
    Sell

Peers & Related Assets

TVTXTravere Therapeutics, Inc.
$50.24-1.7%
VERAVera Therapeutics, Inc.
$25.58-2.4%
MAZEMaze Therapeutics, Inc.
$31.2-5.1%
OBIOOrchestra BioMed Holdings, Inc.
DMACDiaMedica Therapeutics Inc.
UNCYUnicycive Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.